{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:22:55Z","timestamp":1781835775745,"version":"3.54.5"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1780,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005072","name":"Japanese Circulation Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018036","name":"Nippon Shinyaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003348","name":"Fukuda Foundation for Medical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013642","name":"Japan Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013236","name":"MSD Life Science Foundation, Public Interest Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013236","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005072","name":"Japanese Circulation Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003348","name":"Fukuda Foundation for Medical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013642","name":"Japan Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013236","name":"MSD Life Science Foundation, Public Interest Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013236","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Few biomarkers to evaluate pathophysiological changes in extra-cardiac tissues have been identified in patients with heart failure (HF). Fatty acid-binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Measurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospectively followed-up for a composite outcome of all-cause mortality or HF hospitalization. Compared with control subjects, levels of FABP1 were elevated in HF patients [7.9 (6.4\u201311.7) vs. 17.6 (10.4\u201328.9) ng\/mL, P &amp;lt; 0.0001]. There were significant correlations between FABP1 levels and estimated right ventricular systolic pressure and right atrial pressure. During a median follow-up of 12.0 months, there were 55 primary composite endpoints in the HF cohort. The highest FABP1 tertile was associated with a three-fold increased risk of the composite outcome compared with the lowest tertile [95% confidence interval (1.46\u20136.68), P = 0.003], but other conventional hepatobiliary markers did not predict the outcome. After adjusting for age, sex, atrial fibrillation, and N-terminal pro-B-type natriuretic peptide levels, serum FABP1 remained independently associated with the outcome. Adding FABP1 to the model based on clinical factors and N-terminal pro-B-type natriuretic peptide significantly improved the prognostic value (global \u03c72 20.8 vs. 15.5, P = 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum FABP1 levels are elevated in compensated HF patients, and the magnitude of elevation is independently associated with pulmonary hypertension, right atrial hypertension, and worse clinical outcomes. FABP1 may serve as a new potential biomarker for the assessment of hitherto unrecognized derangement of cardio-hepatic interaction in HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13239","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T20:12:38Z","timestamp":1612728758000},"page":"1494-1501","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic Impact of Elevated Fatty Acid-Binding Protein 1 in Patients with Heart Failure"],"prefix":"10.1093","volume":"8","author":[{"given":"Kazuki","family":"Kagami","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]},{"name":"Division of Cardiology, National Defense Medical College , Tokorozawa, Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Sunaga","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]},{"name":"Center for Liberal Arts and Sciences, Ashikaga University , Ashikaga, Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Sorimachi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonari","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Koitabashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Iso","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Adachi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, National Defense Medical College , Tokorozawa, Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kurabayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Obokata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2026012115082777000_ehf213239-bib-0001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tcm.2016.07.005","article-title":"Biomarkers in cardiovascular disease: statistical assessment and section on key novel heart failure biomarkers","volume":"27","author":"Dhingra","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"2026012115082777000_ehf213239-bib-0002","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012115082777000_ehf213239-bib-0003","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jacc.2007.12.048","article-title":"Novel metabolic risk factors for incident heart failure and their relationship with obesity","volume":"51","author":"Bahrami","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012115082777000_ehf213239-bib-0004","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2014.02.617","article-title":"Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure","volume":"64","author":"Tang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012115082777000_ehf213239-bib-0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/eurjhf\/hfn031","article-title":"Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"11","author":"Allen","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026012115082777000_ehf213239-bib-0006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2362.2011.02573.x","article-title":"Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance","volume":"42","author":"Poelzl","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"2026012115082777000_ehf213239-bib-0007","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cardfail.2009.08.002","article-title":"Abnormal liver function in relation to hemodynamic profile in heart failure patients","volume":"16","author":"van Deursen","year":"2010","journal-title":"J Card Fail"},{"key":"2026012115082777000_ehf213239-bib-0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.177.4043.56","article-title":"A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues","volume":"177","author":"Ockner","year":"1972","journal-title":"Science (80-)"},{"key":"2026012115082777000_ehf213239-bib-0009","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1073\/pnas.051619898","article-title":"Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors \u03b1- and \u03b3-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus","volume":"98","author":"Wolfrum","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"2026012115082777000_ehf213239-bib-0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0009-9120(03)00096-1","article-title":"Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility","volume":"36","author":"Pelsers","year":"2003","journal-title":"Clin Biochem"},{"key":"2026012115082777000_ehf213239-bib-0011","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science (80-)"},{"key":"2026012115082777000_ehf213239-bib-0012","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/hep.28945","article-title":"Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure","volume":"65","author":"Karvellas","year":"2017","journal-title":"Hepatology"},{"key":"2026012115082777000_ehf213239-bib-0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.arcmed.2012.11.007","article-title":"Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection","volume":"44","author":"Akbal","year":"2013","journal-title":"Arch Med Res"},{"key":"2026012115082777000_ehf213239-bib-0014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7150\/ijms.40417","article-title":"Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"17","author":"Lu","year":"2020","journal-title":"Int J Med Sci"},{"key":"2026012115082777000_ehf213239-bib-0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081318","article-title":"Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. Schunck W-H, ed","volume":"8","author":"Ishimura","year":"2013","journal-title":"PLoS One"},{"key":"2026012115082777000_ehf213239-bib-0016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/jcm9010164","article-title":"Heart-type fatty acid-binding protein (H-FABP) and its role as a biomarker in heart failure: what do we know so far?","volume":"9","author":"Rezar","year":"2020","journal-title":"J Clin Med"},{"key":"2026012115082777000_ehf213239-bib-0017","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1042\/CS20120004","article-title":"Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure","volume":"124","author":"Liu","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"2026012115082777000_ehf213239-bib-0018","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging Elsevier Inc"},{"key":"2026012115082777000_ehf213239-bib-0019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cccn.2004.09.001","article-title":"Fatty acid-binding proteins as plasma markers of tissue injury","volume":"352","author":"Pelsers","year":"2005","journal-title":"Clin Chim Acta"},{"key":"2026012115082777000_ehf213239-bib-0020","first-page":"561","article-title":"Early increase in serum fatty acid binding protein 4 levels in patients with acute myocardial infarction","volume":"7","author":"Obokata","year":"2018","journal-title":"Eur Hear Journal Acute Cardiovasc Care"},{"key":"2026012115082777000_ehf213239-bib-0021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1194\/jlr.M055798","article-title":"Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity","volume":"56","author":"Ertunc","year":"2015","journal-title":"J Lipid Res"},{"key":"2026012115082777000_ehf213239-bib-0022","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ejhf.785","article-title":"Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure","volume":"19","author":"Voors","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115082777000_ehf213239-bib-0023","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA - J Am Med Assoc"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13239","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/1494\/65927176\/eschf_8_2_1494.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/1494\/65927176\/eschf_8_2_1494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:10:33Z","timestamp":1769026233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/2\/1494\/8381982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,4]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13239","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"2020-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}